Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies

被引:115
作者
Chen, Chun-Bing [1 ,2 ,3 ,4 ,5 ,6 ]
Wu, Ming-Ying [1 ,2 ,3 ,4 ]
Ng, Chau Yee [1 ,2 ,3 ,4 ,5 ]
Lu, Chun-Wei [1 ,2 ,3 ,4 ,5 ,6 ]
Wu, Jennifer [1 ,2 ,3 ,4 ,6 ]
Kao, Pei-Han [1 ,2 ,3 ,4 ,6 ]
Yang, Chan-Keng [4 ,5 ,6 ,7 ]
Peng, Meng-Ting [4 ,6 ,7 ]
Huang, Chen-Yang [4 ,6 ,7 ]
Chang, Wen-Cheng [4 ,6 ,7 ]
Hui, Rosaline Chung-Yee [1 ,4 ]
Yang, Chih-Hsun [1 ,2 ,3 ,4 ]
Yang, Shun-Fa [6 ,8 ,9 ]
Chung, Wen-Hung [1 ,2 ,3 ,4 ,6 ,10 ,11 ]
Su, Shih-Chi [1 ,2 ,3 ,4 ,10 ]
机构
[1] Chang Gung Mem Hosp, Dept Dermatol, Drug Hypersensit Clin & Res Ctr, Linkou, Taiwan
[2] Chang Gung Mem Hosp, Dept Dermatol, Drug Hypersensit Clin & Res Ctr, Taipei, Taiwan
[3] Chang Gung Mem Hosp, Dept Dermatol, Drug Hypersensit Clin & Res Ctr, Keelung, Taiwan
[4] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[5] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan, Taiwan
[6] Chang Gung Mem Hosp, Immune Oncol Ctr Excellence, Linkou, Taiwan
[7] Chang Gung Mem Hosp, Div Hematol Oncol, Dept Internal Med, Linkou, Taiwan
[8] Chung Shan Med Univ, Inst Med, 110 Chien Kuo North Rd,Sect 1, Taichung 402, Taiwan
[9] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan
[10] Chang Gung Mem Hosp, Whole Genome Res Core Lab Human Dis, 222 Maijin Rd, Keelung 204, Taiwan
[11] Xiamen Chang Gung Hosp, Dept Dermatol, Xiamen, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2018年 / 10卷
关键词
acute generalized exanthematous pustulosis; drug rash; eosinophilia; Stevens-Johnson syndrome; toxic epidermal necrolysis; targeted therapy; immunotherapy; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; GENERALIZED EXANTHEMATOUS PUSTULOSIS; LYMPHOCYTE-TRANSFORMATION TEST; ANTI-CD20; MONOCLONAL-ANTIBODY; SYSTEMIC SYMPTOMS DRESS; METASTATIC MELANOMA; DRUG REACTION; SKIN REACTION; BORTEZOMIB TREATMENT;
D O I
10.2147/CMAR.S163391
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the increasing use of targeted anticancer drugs and immunotherapies, there have been a substantial number of reports concerning life-threatening severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms, drug-induced hypersensitivity syndrome, and acute generalized exanthematous pustulosis. Although the potential risks and characteristics for targeted anticancer agent-and immunotherapy-induced SCAR were not well understood, these serious adverse reactions usually result in morbidity and sequela. As a treatment guideline for this devastating condition is still unavailable, prompt withdrawal of causative drugs is believed to be a priority of patient management. In this review, we outline distinct types of SCARs caused by targeted anticancer therapies and immunotherapies. Also, we discuss the clinical course, latency, concomitant medication, tolerability of rechallenge or alternatives, tumor response, and mortality associated with these devastating conditions. Imatinib, vemurafenib, and rituximab were the top three offending medications that most commonly caused SJS/TEN, while EGFR inhibitors were the group of drugs that most frequently induced SJS/TEN. For drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome and acute generalized exanthematous pustulosis, imatinib was also the most common offending drug. Additionally, we delineated 10 SCAR cases related to innovative immunotherapies, including PD1 and CTLA4 inhibitors. There was a wide range of latency periods: 5.5-91 days (median). Only eight of 16 reported patients with SCAR showed clinical responses. Targeted anticancer drugs and immunotherapies can lead to lethal SCAR (14 deceased patients were identified as suffering from SJS/TEN). The mortality rate of TEN was high: up to 52.4%. The information compiled herein will serve as a solid foundation to formulate ideas for early recognition of SCAR and to discontinue offending drugs for better management.
引用
收藏
页码:1259 / 1273
页数:15
相关论文
共 50 条
  • [31] A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea
    Kang, Dong Yoon
    Yun, James
    Lee, Suh-Young
    Koh, Young-Il
    Sim, Da Woon
    Kim, Sujeong
    Nam, Young Hee
    Park, Jung-Won
    Kim, Sae Hoon
    Ye, Young-Min
    Park, Hye-Kyung
    Kim, Min-Hye
    Jee, Young-Koo
    Jung, Jae-Woo
    Yang, Min-Suk
    Kim, Sang-Heon
    Lee, Jun Kyu
    Kim, Cheol-Woo
    Hur, Gyu Young
    Kim, Mi-Yeong
    Park, Seoung Ju
    Kwon, Yong Eun
    Choi, Jeong-Hee
    Kim, Joo-Hee
    Kim, Sang Hyon
    La, Hyen O.
    Kang, Min-Gyu
    Park, Chan Sun
    Lee, Sang Min
    Jeong, Yi Yeong
    Kim, Hee-Kyoo
    Jin, Hyun Jung
    Jeong, Jae-Won
    Lee, Jaechun
    Lee, Yong Won
    Lee, Seung Eun
    Kim, Myoung Shin
    Kang, Hye-Ryun
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (02) : 929 - +
  • [32] Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China
    Deng, Min
    Su, Yuwen
    Wu, Ruifang
    Li, Siying
    Tang, Guishao
    Kuang, Qiqi
    Luo, Xin
    Zhu, Yanshan
    Shen, Weiyun
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
  • [33] Medication Associations with Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System
    Godfrey, Hannah
    Jedlowski, Patrick
    Thiede, Rebecca
    [J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2024, 28 (01) : 51 - 58
  • [34] Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children
    Manuyakorn, Wiparat
    Likkasittipan, Plernpit
    Wattanapokayakit, Sukanya
    Suvichapanich, Supharat
    Inunchot, Wimala
    Wichukchinda, Nuanjun
    Khongkhatithuml, Chaiyos
    Thampratankul, Lunliya
    Kamchaisatian, Wasu
    Benjaponpitak, Suwat
    Mahasirimongkol, Surakameth
    [J]. EPILEPSY RESEARCH, 2020, 162
  • [35] Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions
    Villanueva-Paz, Marina
    Niu, Hao
    Segovia-Zafra, Antonio
    Medina-Caliz, Inmaculada
    Sanabria-Cabrera, Judith
    Lucena, M. Isabel
    Andrade, Raul J.
    Alvarez-Alvarez, Ismael
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (22)
  • [36] Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics
    Tempark, Therdpong
    John, Shobana
    Rerknimitr, Pawinee
    Satapornpong, Patompong
    Sukasem, Chonlaphat
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [37] Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions
    Wang, Chuang-Wei
    Dao, Ro-Lan
    Chung, Wen-Hung
    [J]. CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 16 (04) : 339 - 345
  • [38] Severe cutaneous adverse reactions: impact of immunology, genetics, and pharmacology
    Harp, Joanna L.
    Kinnebrew, Melissa A.
    Shinkai, Kanade
    [J]. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2014, 33 (01) : 17 - 27
  • [39] Bronchopulmonary involvement in severe cutaneous adverse reactions
    de Prost, N.
    Mekontso-Dessap, A.
    Valeyrie-Allanore, L.
    Maitre, B.
    [J]. REANIMATION, 2013, 22 (01): : 73 - 79
  • [40] Genetic markers of severe cutaneous adverse reactions
    Jung, Jae-Woo
    Kim, Jae-Yeol
    Park, In-Won
    Choi, Byoung-Whui
    Kang, Hye-Ryun
    [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2018, 33 (05) : 867 - 875